Skip to main content

Boehringer Ingelheim – Schizophrenia

 

 

The study is looking to prevent patients with Schizophrenia from becoming worse or relapsing over a 6 month time period.

Sponsors: Boehringer Ingelheim

Phase : 2

Indication: Schizophrenia

Age: 18 years to 55 years

Category: Treatment

 

For more information please visit https://clinicaltrials.gov/ct2/show/NCT03351244

 

 

Studies Currently Available At

Sign Up For This Study